PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go:
Expired
investment:
Withheld
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
Brompton's bicycle hire allows people to hire folding bicycles from hiring stations. The hiring stations (docks) are sold to partners. The company have already sold 44 docks to partners. They are looking for investment to prepare the business for international expansion. The funding will used to increase the size of their network by placing more docks in strategic locations. Their service will also be developed with the funds, working on their customer service and developing their skills.
days to go:
Expired
investment:
£380,000
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go:
Expired
investment:
£65,004
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.
days to go:
Expired
investment:
Withheld
The Stirling Electric Motorcycle Company presents a futuristic motorcycle experience available today! The SEMC "SINATRA" delivers an exhilarating ride, easy maintenance, and the finest ride quality in its category. Whether you're a new, returning, or transitioning rider, enjoy the benefits of electric riding without the complexities and costs of advanced licensing. In numerous regions, motorcycles with up to 11 kilowatts of continuous power have more lenient licensing rules, such as in the UK where an 11kw SINATRA can be legally ridden after completing a one-day basic training course.
days to go:
Expired
investment:
£42,000
